Neuropharmacological treatment of sleep-related breathing disorders
First Claim
1. A method of preventing or ameliorating sleep-related breathing disorders the method comprising administering to a patient in need thereof an effective amount of a combination of agents having glutamate receptor antagonistic activity and glycine antagonistic activity within the central nervous system, wherein the agent having glutamate receptor antagonistic activity is selected from the group consisting of CGS19755 and memantine, and the agent having glycine receptor antagonistic activity is selected from the group consisting of MNQX and picrotoxin.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess glutamate-related and/or glycine-related pharmacological activity or that modulate the release of glutamate, glycine, or both from nerve terminals with the central nervous system.
-
Citations
4 Claims
- 1. A method of preventing or ameliorating sleep-related breathing disorders the method comprising administering to a patient in need thereof an effective amount of a combination of agents having glutamate receptor antagonistic activity and glycine antagonistic activity within the central nervous system, wherein the agent having glutamate receptor antagonistic activity is selected from the group consisting of CGS19755 and memantine, and the agent having glycine receptor antagonistic activity is selected from the group consisting of MNQX and picrotoxin.
- 3. A method of preventing or ameliorating sleep-related breathing disorders the method comprising administering to a patient in need thereof an effective amount of an agent or combination of agents having the ability to prevent the release of both glutamate and glycine activity within the central nervous system, wherein the agent having glutamate receptor antagonistic activity is selected from the group consisting of CGS19755 and memantine, and the agent having glycine receptor antagonistic activity is selected from the group consisting of MNQX and picrotoxin.
Specification